Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-29

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1b/2a, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE investigational vaccine compared to placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT03302897

Leprosy

COMPLETED PHASE1

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

NCT00111553

Leishmaniasis, Cutaneous

COMPLETED PHASE1

Miltefosine and GM-CSF in Cutaneous Leishmaniasis

NCT03023111

Cutaneous Leishmaniasis

COMPLETED PHASE3

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

NCT00111514

Leishmaniasis, Mucocutaneous

COMPLETED PHASE1

Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)

NCT00600548

Treatment of Cutaneous Leishmaniasis in Brazil.

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed clinical trial will establish an initial safety profile for the vaccine in a region endemic for leprosy. The trial will enroll both healthy participants and paucibacillary leprosy patients receiving standard-of-care therapy. Safety at the lower vaccine dose will be demonstrated in healthy participants prior to antigen dose-escalation. Further, safety in all healthy participants will be demonstrated prior to enrolling leprosy patients.

Participants will be randomized within each Group to receive three doses of vaccine or placebo administered IM on Days 0, 28, and 56. Participants will be monitored for one year following the last study injection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leprosy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

This is a double-blind study. Participants, investigators, study personnel performing any study-related assessments following study injection, and laboratory personnel performing immunology assays will be blinded to treatment assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose

2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.

Group Type EXPERIMENTAL

LEP-F1 + GLA-SE

Intervention Type BIOLOGICAL

Leprosy antigen formulated with an adjuvant.

High dose

10 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in healthy participants.

Group Type EXPERIMENTAL

LEP-F1 + GLA-SE

Intervention Type BIOLOGICAL

Leprosy antigen formulated with an adjuvant.

TBD dose in patients

TBD μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0, 28, and 56 in paucibacillary leprosy patients. Dose will be determined by safety and immunogenicity data from healthy participants.

Group Type EXPERIMENTAL

LEP-F1 + GLA-SE

Intervention Type BIOLOGICAL

Leprosy antigen formulated with an adjuvant.

Placebo

Sterile normal saline for injection will be administered by IM injection on Days 0, 28, and 56 in healthy participants and paucibacillary leprosy patients.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Sterile normal saline for injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LEP-F1 + GLA-SE

Leprosy antigen formulated with an adjuvant.

Intervention Type BIOLOGICAL

Placebo

Sterile normal saline for injection.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LepVax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women between 18 and 55 years old.
2. They should be in good general health, confirmed by a medical history and physical examination, with negative clinical evaluation for leprosy.
3. Female participants of childbearing age should have a negative serum pregnancy test at screening and a negative urine pregnancy test on study vaccination days (D0, D28 and D56). They must not be breast-feeding and are required to use at least one contraceptive method from the time of study inclusion (Day 0) until 30 days after the last injection if they have sex with men.
4. Screening laboratory tests with normal, within laboratory reference limits for:: sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine, glucose, total leukocyte count, hemoglobin and platelet count. Abnormal results may be repeated at the discretion of the Principal Investigator and/or sub-investigators, who may share doubts with the sponsor's Scientific Leader and if necessary with the DSMB.
5. Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
6. Normal or not clinically significant urinalysis as determined by the study doctor or designee. Abnormal results may be repeated at the discretion of the Principal Investigator.
7. Must be able to complete the study adverse events diary.
8. Must consent to participate in the study, be able and willing to make all evaluation visits, be accessible by telephone or home visits, and live in the region until study follow-up completion.
9. Having completed the primary vaccination course for Covid 19, at least 14 days before inclusion in the study. If 14 days have not been completed, the participant may be rescheduled for a new eligibility assessment

Participants must meet ALL of the following criteria listed below to be included in the study:

1. Men and women between 18 and 55 years old.
2. Diagnosis of PB leprosy (BI=0) before MDT treatment
3. Female participants of childbearing age should have a negative serum pregnancy test at screening and a negative urine pregnancy test on study vaccination days (D0, D28 and D56). They must not be breast-feeding and are required to use at least one contraceptive method from the time of study inclusion (Day 0) until 30 days after the last injection if they have sex with men.
4. Screening laboratory tests with normal, within laboratory reference limits for: sodium, potassium, AST, ALT, total bilirubin, alkaline phosphatase, creatinine, glucose, total leukocyte count, hemoglobin and platelet count. Abnormal results may be repeated at the discretion of the Principal Investigator and/or sub-investigators, who may share doubts with the sponsor's Scientific Leader and if necessary with the DSMB.
5. Negative serological tests for: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.
6. Normal or not clinically significant urinalysis as determined by the study doctor or designee. Abnormal results may be repeated at the discretion of the Principal Investigator.
7. Must be able to complete the study adverse events diary.
8. Must consent to participate in the study, be able and willing to make all evaluation visits, be accessible by telephone or home visits, and live in the region until study follow-up completion.
9. Having completed the primary vaccination course for Covid 19, at least 14 days before inclusion in the study. If 14 days have not been completed, the participant may be rescheduled for a new eligibility assessment

Exclusion Criteria

Individuals who meet ANY of the following criteria will be considered ineligible:

1. History of infection with Mycobacterium leprae.
2. History of exposure to experimental products containing GLA-SE.
3. History of active or documented latent tuberculosis.
4. History of previous infection with other non-tuberculous mycobacteria.
5. Participation in another trial protocol and/or receipt of any trial products in the last 3 months prior to screening.
6. Treatment with immunosuppressive drugs (eg oral or injected steroids, such as prednisone; high doses of inhaled steroids) or cytotoxic therapies (eg chemotherapy or radiation) within 6 months prior to screening.
7. Have received blood transfusion within the last 3 months prior to screening.
8. Donated blood products (platelets, whole blood, plasma, etc.) within the last month prior to screening.
9. Received any vaccine 1 month prior to screening or planned immunizations during the follow-up from D0 to D63 and D154 to D168.
10. History of autoimmune disease or other immunosuppressive causes.
11. History of any other acute or chronic decompensated disease (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, haematological, metabolic or renal disease, uncontrolled hypertension) or use of medication that, in the opinion of the Principal Investigator, may interfere with safety or immunogenicity of the vaccine.
12. Rash, tattoos or any other dermatological condition that may adversely affect the injection site of the vaccine or interfere with its evaluation.
13. Body mass index (BMI) ≥ 32.
14. Systemic arterial hypertension (systolic \> 150 or diastolic \> 95).
15. History of psychiatric illness with current medication use.
16. Alcohol or drug abuse in the last 6 months prior to screening.
17. Chronic smoker (1 pack or more per day).
18. History of previous anaphylaxis or severe allergic reaction to unknown vaccines or allergens.
19. Individuals who do not wish to cooperate with all procedures recommended in the study protocol.

Individuals who meet ANY of the following criteria will be considered ineligible:

1. Previous treatment for leprosy.
2. History of exposure to experimental products containing GLA-SE.
3. History of active or documented latent tuberculosis.
4. History of previous infection with other non-tuberculous mycobacteria.
5. Participation in another trial protocol and/or receipt of any trial products in the last 3 months prior to screening.
6. Treatment with immunosuppressive drugs (eg oral or injected steroids, such as prednisone; high doses of inhaled steroids) or cytotoxic therapies (eg chemotherapy or radiation) within 6 months prior to screening.
7. Have received blood transfusion within the last 3 months prior to screening.
8. Donated blood products (platelets, whole blood, plasma, etc.) within the last month prior to screening.
9. Received any vaccine 1 month prior to screening or planned immunizations during the follow-up from D0 to D63 and D154 to D168.
10. History of autoimmune disease or other immunosuppressive causes.
11. History of any other acute or chronic decompensated disease (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, haematological, metabolic or renal disease, uncontrolled hypertension) or use of medication that, in the opinion of the Principal Investigator, may interfere with safety or immunogenicity of the vaccine.
12. Rash, tattoos or any other dermatological condition that may adversely affect the injection site of the vaccine or interfere with its evaluation.
13. Body mass index (BMI) ≥ 32.
14. Systemic arterial hypertension (systolic \> 150 or diastolic \> 95).
15. History of psychiatric illness with current medication use.
16. Alcohol or drug abuse in the last 6 months prior to screening.
17. Chronic smoker (1 pack or more per day).
18. History of previous anaphylaxis or severe allergic reaction to unknown vaccines or allergens.
19. Individuals who do not wish to cooperate with all procedures recommended in the study protocol.

Vital signs are performed after participants have sat for five minutes without hot or cold drinks or smoking for the past five minutes. Vital signs can be performed up to three times to allow resolution of transient conditions.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes